Drugs /

bt8009

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for bt8009

Bt8009 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating bt8009, 1 is phase 1/phase 2 (1 open).

PVRL4 Expression is the most frequent biomarker inclusion criterion for bt8009 clinical trials.

Breast carcinoma, esophageal carcinoma, and gastric carcinoma are the most common diseases being investigated in bt8009 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bt8009
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bt8009 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bt 8009, bt-8009
Drug Target(s) [2]:
PVRL4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.